ArticleDiabetes care2023
Effect of CGM Access Expansion on Uptake Among Patients on Medicaid With Diabetes.
Article in Diabetes care, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06638099 (Increasing Use of Continuous Glucose Monitors Among Patients With Type 2 Diabetes), which is not on this map. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Increasing Use of Continuous Glucose Monitors Among Patients With Type 2 Diabetes
Who cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 39 citations in OpenAlex.
- Equity of Continuous Glucose Monitoring in Children and Young People With Type 1 Diabetes: A Systematic Review.Pediatric diabetes · 2025Pooled it
- Digital management of diabetes global research trends: a bibliometric study.Frontiers in medicine · 2025Pooled it
- US race/ethnic disparities in diabetes technologies: a systematic review and meta-analysis of 950 000 individuals.Journal of the Endocrine Society · 2026Review
- Inequity in Continuous Glucose Monitor (CGM) Prescribing Behaviors in Primary Care.Journal of general internal medicine · 2026Article
- Continuous Glucose Monitoring in Type 2 Diabetes: Clinical Outcomes, Disparities in Access, and Cost-effectiveness.Current diabetes reports · 2026Review
- Tailoring interventions to close gaps in diabetes mellitus care.Nature reviews. Endocrinology · 2026Review
- Barriers to use of continuous glucose monitoring among adults with type 2 diabetes.Diabetes research and clinical practice · 2026Article
- A Digital Health Framework to Assess Glycemia and Physical Activity in Kidney Transplant Candidates: A Pilot Study.Transplantation direct · 2026Article
- The forgotten - overcoming challenges in diabetes care for marginalized populations.Expert review of endocrinology & metabolism · 2025Review
- Expanding Access to Continuous Glucose Monitoring in Medicare Patients Receiving Specialty Diabetes Care: A Quality Improvement Project.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2025Article
- SCI - U: Validation of an updated Self-Care Inventory for contemporary diabetes management in adolescents with type 1 diabetes.Diabetes research and clinical practice · 2025Article
- Article
- Adapting the NIMHD Research Framework for Type 2 Diabetes-Related Disparities.Current diabetes reports · 2025Review
- Patient perspectives on continuous glucose monitoring system (CGMS) for diabetes in Malaysia: a vital voice in health technology assessment (HTA) informing decision-making.International journal of technology assessment in health care · 2025Article
- Measurement of serum 1,5-AG provides insights for diabetes management and the anti-viral immune response.Cellular and molecular life sciences : CMLS · 2025Article
- Impact of a Nurse Practitioner-Led Diabetes Program on Barriers to CGM Use in a Federally Qualified Health Center After Medicaid Expansion.Journal of diabetes research · 2025Article
- Disparities in Continuous Glucose Monitoring Among Patients Receiving Care in Federally Qualified Health Centers.JAMA network open · 2024Article
- Impact of continuous glucose monitoring on emergency department visits and all-cause hospitalization rates among Medicaid beneficiaries with type 2 diabetes treated with multiple daily insulin or basal insulin therapy.Journal of managed care & specialty pharmacy · 2024Article
- Continuous glucose monitoring for self-management of diabetes in people living with type 2 diabetes mellitus on basal insulin therapy: A microsimulation model and cost-effectiveness analysis from a US perspective with relevance to Medicaid.Journal of managed care & specialty pharmacy · 2024Article
- Continuous Glucose Monitor: Reclaiming Type 2 Diabetes Self-efficacy and Mitigating Disparities.Journal of the Endocrine Society · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
objectiveCurrent studies on continuous glucose monitor (CGM) uptake are revealing for significant barriers and inequities for CGM use among patients from socially underprivileged communities. This study explores the effect of full subsidies regardless of diabetes type on CGM uptake and HbA1c outcomes in a U.S. adult patient population on Medicaid. RESEARCH DESIGN AND
methodsThis retrospective cohort study examined 3,036 adults with diabetes enrolled in a U.S. Medicaid program that fully subsidized CGM. CGM uptake and adherence were assessed by CGM prescription and dispense data, including more than one fill and adherence by medication possession ratio (MPR). Multivariate logistic regression evaluated predictors of CGM uptake. Pre- and post-CGM use HbA1c were compared.
resultsCGM were very well received by both individuals with type 1 diabetes and individuals with type 2 diabetes with similar high fill adherence levels (mean MPR 0.78 vs. 0.72; P = 0.06). No significant difference in CGM uptake outcomes were noted among major racial/ethnic groups. CGM use was associated with improved HbA1c among those with type 2 diabetes (-1.2% [13.1 mmol/mol]; P < 0.001) that was comparable between major racial/ethnic groups and those with higher fill adherence achieved greater HbA1c reduction (-1.4% [15.3 mmol/mol]; P < 0.001) compared with those with lower adherence (-1.0% [10.9 mmol/mol]; P < 0.001).
conclusionsCGM uptake disparities can largely be overcome by eliminating CGM cost barriers. CGM use was associated with improved HbA1c across all major racial/ethnic groups, highlighting broad CGM appeal, utilization, and effectiveness across an underprivileged patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.